Amgen (AMGN) Submits MAA tto EMA for Evolocumab as High Cholesterol Treatment
Tweet Send to a Friend
Amgen (Nasdaq: AMGN) announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE